¿Ventajas y desventajas de iSGLT2 vs análogos GLP-1 en adultos mayores?
Cuales con las ventajas y desventajas comparativas entre los medicamentos SLGT2 y GLP1R en adultos mayores con Diabetes Mellitus
Comparative Advantages and Disadvantages of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Older Adults with Type 2 Diabetes Mellitus: A Comprehensive Clinical Evidence Review
This comprehensive clinical analysis reveals that sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1RA) represent fundamentally different therapeutic approaches to managing type 2 diabetes in older adults, each offering distinct cardioprotective and renoprotective benefits alongside specific safety considerations. SGLT2 inhibitors demonstrate superior efficacy in preventing heart failure hospitalizations and slowing renal disease progression, while GLP-1 receptor agonists provide superior glycemic control, more substantial weight loss, and potentially greater protection against stroke. The evidence-based comparison reveals critical differences in adverse event profiles, adherence patterns, and applicability across different phenotypes of older adults, with particular relevance when considering frailty status, renal function, and cardiovascular risk factors. This analysis synthesizes contemporary clinical trial data, meta-analytic findings, and real-world observational evidence to provide clinicians with the evidence foundation necessary for individualized therapeutic decision-making in this vulnerable population, while acknowledging significant gaps in the representation of very elderly and frail populations in clinical research.
Epidemiological Context and Clinical Significance in Older Populations
The management of type 2 diabetes mellitus in older adults represents one of the most pressing clinical challenges in contemporary geriatric medicine, particularly given the dramatic expansion of new pharmacological options that extend beyond conventional glucose-lowering mechanisms[1][2]. The older adult population with type 2 diabetes encompasses increasingly heterogeneous clinical phenotypes, ranging from fit, active individuals to those with profound frailty, multiple comorbidities, and limited life expectancy. This heterogeneity fundamentally shapes therapeutic decision-making, as the evidence base for both SGLT2 inhibitors and GLP-1 receptor agonists has been predominantly derived from clinical trials enrolling younger, healthier populations, resulting in substantial representation gaps for individuals over seventy-five years of age and those meeting criteria for moderate to severe frailty[2][3].
The prevalence of heart failure and chronic kidney disease in older adults with type 2 diabetes has created a compelling clinical need for therapies that address cardioprotective and renoprotective outcomes beyond glycemic control alone[1][2][4]. Despite favorable clinical trial data and updated clinical guidelines recommending the use of SGLT2 inhibitors in frail older adults, prescribing hesitance persists in real-world clinical practice, partly attributable to limited therapeutic experience with these drug classes in populations with advanced age and significant frailty[1]. Similarly, GLP-1 receptor agonists, despite demonstrating substantial benefits in cardiovascular risk reduction, continue to be underutilized in older populations due to concerns regarding gastrointestinal adverse events and tolerability in this age group[5]. The clinical significance of this comparison extends beyond isolated efficacy endpoints to encompass the complex interplay between drug efficacy, safety, tolerability, adherence, and overall impact on quality of life and functional status in older individuals.
Mechanisms of Action and Fundamental Pharmacological Differences
Understanding the distinct mechanistic pathways of SGLT2 inhibitors and GLP-1 receptor agonists provides essential context for predicting their differential clinical effects in older adults. SGLT2 inhibitors function through selective inhibition of sodium-glucose cotransporter-2 located in the proximal tubule of the kidney, which normally reabsorbs approximately eighty to ninety percent of filtered glucose[6]. This mechanism results in increased urinary glucose excretion, producing an osmotic diuretic effect that reduces blood glucose levels while simultaneously decreasing intravascular volume, thereby reducing preload and improving cardiac hemodynamics[1][7]. The mechanism also generates favorable metabolic effects including mild diuresis, reduction in blood pressure, decreased uric acid levels, and reduced serum potassium concentrations, though the osmotic diuresis simultaneously increases the risk of volume depletion and associated complications[6][7].
In contrast, GLP-1 receptor agonists exert their glucose-lowering effects through activation of glucagon-like peptide-1 receptors distributed across multiple physiological systems[5][8]. These agents enhance glucose-dependent insulin secretion from pancreatic beta cells in response to meals, simultaneously suppressing glucagon secretion from alpha cells, thereby reducing hepatic glucose production[5]. Beyond glycemic effects, GLP-1 receptor agonists delay gastric emptying, promoting satiety and contributing to substantial weight reduction of typically three to six kilograms greater than SGLT2 inhibitors[3][9]. The GLP-1 receptor distribution extends throughout the central nervous system and peripheral tissues, including vascular endothelium and myocardium, creating multiple sites for cardioprotective signaling that may operate through mechanisms distinct from glucose lowering[5][8].
These fundamentally different mechanisms generate divergent clinical profiles that become particularly relevant in older populations. SGLT2 inhibitors produce their cardioprotective and renoprotective benefits primarily through hemodynamic and systemic metabolic mechanisms that are largely independent of glucose control, whereas GLP-1 receptor agonists contribute to cardiovascular protection through multiple pathways including weight reduction, blood pressure lowering, improvements in lipid profiles, and direct endothelial effects[3][9]. Importantly, SGLT2 inhibitors generate relatively modest improvements in hemoglobin A1c (typically 0.5 to 1.0 percent reductions) whereas GLP-1 receptor agonists achieve more substantial glycemic control with hemoglobin A1c reductions typically ranging from 1.0 to 1.8 percent depending on the specific agent and baseline control[10].
Cardiovascular Outcomes and Event Prevention
The comparative cardiovascular efficacy of SGLT2 inhibitors and GLP-1 receptor agonists in older adults with type 2 diabetes represents one of the most extensively investigated aspects of these drug classes, with important nuances that require careful clinical interpretation. A comprehensive meta-analysis directly comparing both drug classes in elderly patients revealed comparable risks for major adverse cardiovascular events, myocardial infarction, stroke, and hypoglycemia between SGLT2 inhibitors and GLP-1 receptor agonists[11]. However, this apparent equivalence masks important differential effects on specific cardiovascular endpoints that have substantial clinical relevance for therapeutic decision-making.
Regarding heart failure outcomes, the evidence demonstrates more consistent and pronounced benefits of SGLT2 inhibitors over GLP-1 receptor agonists in older populations[11][12][9]. Patients at higher risk of heart failure may derive greater benefit from SGLT2 inhibitors than from GLP-1 receptor agonists, particularly due to the superior ability of SGLT2 inhibitors to prevent hospitalizations for heart failure[3][9]. In older or frail patients with both type 2 diabetes and established heart failure, SGLT2 inhibitors demonstrate consistent associations with substantial reductions in hospitalizations for heart failure, with risk reductions typically ranging from twenty-five to thirty-one percent compared with placebo or alternative glucose-lowering agents[2][4]. A real-world observational study of very elderly patients aged seventy-five years or older with heart failure with reduced ejection fraction identified SGLT2 inhibitor treatment as an independent protective factor, with multivariate analysis demonstrating a hazard ratio of 0.39 for all-cause mortality[4]. These heart failure benefits appear to manifest more consistently across the older age spectrum than GLP-1 receptor agonist effects.
The stroke prevention profile presents a contrasting pattern of cardiovascular benefit. GLP-1 receptor agonists demonstrate more robust protection against ischemic stroke in patients with type 2 diabetes, with meta-analytic evidence indicating approximately thirteen percent reduction in total stroke risk and significant reductions in nonfatal stroke events[8]. Large randomized controlled trials including the LEADER trial (Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes) and SUSTAIN-6 trial demonstrated substantial stroke risk reductions with GLP-1 receptor agonist therapy[8]. The mechanisms underlying this superior stroke prevention with GLP-1 receptor agonists likely involve multiple pathways including improved endothelial function, reduced systemic inflammation, enhanced nitric oxide availability, and mitigation of blood-brain barrier dysfunction during acute ischemic events[8]. In contrast, SGLT2 inhibitors have not demonstrated comparable stroke protection in older populations, and this differential benefit represents an important consideration when selecting between therapies for patients at particularly high baseline stroke risk.
Regarding all-cause mortality, the evidence suggests comparable efficacy between both drug classes in older adults generally, though nuances emerge when examining specific subpopulations. In older or frail patients with concurrent type 2 diabetes and heart failure, SGLT2 inhibitors demonstrate consistent associations with reductions in all-cause mortality, with risk reductions typically ranging from fifteen to twenty percent[2][4]. GLP-1 receptor agonists similarly demonstrate all-cause mortality benefits in older populations, with meta-analytic data indicating approximately fifteen percent mortality reduction[5]. The similar magnitude of mortality benefit between these drug classes in broader older populations suggests that selection between agents may appropriately be based on consideration of other clinical parameters including renal function, frailty status, and specific cardiovascular risk phenotypes.
Renal Outcomes and Chronic Kidney Disease Progression
The comparative effects of SGLT2 inhibitors and GLP-1 receptor agonists on renal outcomes represent a critical differentiating feature between these drug classes, with important implications for older adults given the high prevalence of chronic kidney disease in this population. A systematic review and network meta-analysis comparing renal outcomes revealed that SGLT2 inhibitors demonstrated superiority to GLP-1 receptor agonists in preventing chronic kidney disease progression, regardless of the presence of albuminuria[13]. In patients with chronic kidney disease with albuminuria, SGLT2 inhibitors reduced renal risk by twenty-five percent compared with GLP-1 receptor agonists (risk ratio 0.75; 95% confidence interval 0.63-0.89), and in patients without albuminuria, SGLT2 inhibitors reduced renal risk by forty-one percent (risk ratio 0.59; 95% confidence interval 0.44-0.79)[13].
A comparative effectiveness study conducted in a large commercially insured population with type 2 diabetes and chronic kidney disease found that patients treated with SGLT2 inhibitors experienced fourteen percent lower risk of nonfatal myocardial infarction or stroke compared with GLP-1 receptor agonist recipients[12]. When stratified by chronic kidney disease stage, patients with albuminuria and normal or near-normal estimated glomerular filtration rate appeared to experience the greatest relative benefit of SGLT2 inhibitors[12], suggesting that the renoprotective advantage of SGLT2 inhibitors may be most pronounced in specific phenotypes of kidney disease characterized by preserved renal filtration capacity with proteinuria.
Evidence specifically examining renal outcomes in very elderly populations with diabetic kidney disease demonstrates continued benefits of SGLT2 inhibitors into advanced age. A propensity-matched study of patients aged seventy-five years and older with diabetic kidney disease found that those initiating SGLT2 inhibitors experienced significantly slower rates of estimated glomerular filtration rate decline compared with recipients of other glucose-lowering medications, with an absolute difference of 0.99 mL/min/1.73 m²/year (95% confidence interval 0.5 to 1.38; p<0.001)[14]. Additionally, composite renal outcomes including forty percent reduction in estimated glomerular filtration rate or progression to end-stage kidney disease occurred in thirty-eight patients in the SGLT2 inhibitor group compared with fifty-seven in the control group (hazard ratio 0.64; 95% confidence interval 0.42-0.97)[14]. Importantly, these benefits manifested in both patients with and without proteinuria, suggesting broad applicability of SGLT2 inhibitors for renal protection across phenotypic variants of diabetic kidney disease in older adults.
GLP-1 receptor agonists also demonstrate renoprotective effects, with meta-analytic data indicating approximately twenty-two percent reduction in composite kidney outcomes in older adults[5]. However, the magnitude of renal benefit and the specificity of renal outcomes addressed suggest that SGLT2 inhibitors offer advantages particularly for slowing estimated glomerular filtration rate decline and preventing progression to end-stage kidney disease, while GLP-1 receptor agonists provide more generalized kidney protection including reductions in albuminuria across diverse chronic kidney disease phenotypes. The practical implication is that selection of SGLT2 inhibitors may be particularly justified in older patients with rapidly declining renal function or advanced chronic kidney disease stages where preservation of residual renal function becomes clinically paramount.
Safety Profile: A Detailed Comparative Analysis
The safety profile comparison between SGLT2 inhibitors and GLP-1 receptor agonists reveals important differences in both the frequency and clinical significance of adverse events, with particular relevance for older populations who frequently experience polypharmacy and age-related physiological changes that may amplify drug safety concerns. Understanding these safety differences is essential for informed clinical decision-making, as the perception of safety sometimes diverges substantially from empirical evidence in older populations.
Genital and Urinary Tract Infections
One of the most consistently identified differential safety signals between SGLT2 inhibitors and GLP-1 receptor agonists involves infectious complications of the genitourinary system. The osmotic diuretic effect of SGLT2 inhibitors, which increases urinary glucose excretion, creates favorable conditions for fungal proliferation within the genitourinary tract[15][16]. A population-based retrospective cohort study of older women and men with diabetes aged sixty-six years and older found that incident use of SGLT2 inhibitors was associated with a 2.47-fold increased risk of genital mycotic infection within thirty days compared with dipeptidyl peptidase-4 inhibitor recipients (adjusted hazard ratio 2.47; 95% confidence interval 2.08-2.92; p<0.001)[16]. Notably, this study found no significant increased risk of urinary tract infection with SGLT2 inhibitors (adjusted hazard ratio 0.89; 95% confidence interval 0.78-1.00; p=0.05), suggesting that the genitourinary infection risk is primarily restricted to fungal pathogens[16].
A meta-analysis examining safety of SGLT2 inhibitors in elderly patients revealed that SGLT2 inhibitors were associated with a six-fold increased risk of genital tract infections compared with placebo (risk ratio 6.55; 95% confidence interval 2.09-20.5)[17]. While these infections are generally mild to moderate in severity and infrequently require treatment discontinuation, the substantial increase in infection risk represents an important counseling point for older patients, particularly older women who may have reduced tolerance for recurrent genital infections. In contrast, GLP-1 receptor agonists have not been associated with increased genital infection risk in clinical trials or post-marketing surveillance data[18]. The practical implications suggest that GLP-1 receptor agonists may be preferentially selected in older patients with recurrent genital candidiasis or prior predisposition to urogenital infections.
Diabetic Ketoacidosis: Risk Stratification and Clinical Monitoring
SGLT2 inhibitors substantially increase the risk of a specific and potentially life-threatening complication termed euglycemic diabetic ketoacidosis, distinct from the hyperglycemic ketoacidosis traditionally associated with diabetes[6]. This rare but serious complication represents one of the most important safety distinctions between SGLT2 inhibitors and GLP-1 receptor agonists. Euglycemic diabetic ketoacidosis develops through a distinctive pathophysiological process whereby SGLT2 inhibitor-induced glucosuria produces a significant carbohydrate deficit, resulting in decreased blood glucose concentrations and reduced insulin secretion[6]. The reduction in insulin concentrations eliminates insulin's anti-lipolytic activity, thereby increasing production of free fatty acids that are converted into ketone bodies through hepatic beta-oxidation[6]. The clinical presentation of euglycemic diabetic ketoacidosis differs from conventional hyperglycemic diabetic ketoacidosis in that blood glucose levels may remain within normal or only mildly elevated ranges (typically less than 250 mg/dL), creating a substantial diagnostic delay because clinicians may not recognize ketoacidosis in a diabetic patient with near-normal glucose values[6].
Common precipitating factors for euglycemic diabetic ketoacidosis in SGLT2 inhibitor users include acute illness requiring reduced oral intake, surgical procedures with perioperative stress, excessive alcohol consumption, and adoption of low-carbohydrate or ketogenic diets[6]. The risk of euglycemic diabetic ketoacidosis appears higher in patients using SGLT2 inhibitors specifically for diabetes management compared with those using these agents for heart failure or chronic kidney disease, suggesting that the magnitude of hyperglycemic control pressure influences ketoacidosis risk[6]. Clinical recommendations include counseling patients about the need to discontinue SGLT2 inhibitors during periods of acute illness or reduced oral intake, avoiding low-carbohydrate diets, limiting alcohol consumption, and discontinuing SGLT2 inhibitors three to four days prior to elective surgery[6]. Notably, GLP-1 receptor agonists have not been associated with euglycemic diabetic ketoacidosis, representing a significant safety advantage of this drug class[18].
Acute Kidney Injury and Volume Depletion
The osmotic diuretic effect of SGLT2 inhibitors raises clinical concern regarding acute kidney injury and volume depletion, concerns that are particularly relevant in older populations who may have reduced physiological reserve and higher baseline acute kidney injury risk[2][15][17]. Paradoxically, meta-analytic evidence examining acute kidney injury in elderly patients reveals that SGLT2 inhibitors were actually associated with significantly lower risk of acute kidney injury compared with placebo (risk ratio 0.73; 95% confidence interval 0.62-0.87)[17]. Similarly, a real-world pharmacovigilance analysis of adverse event reports identified that acute kidney injury was associated with SGLT2 inhibitors in younger adults (adjusted reporting odds ratio 1.97; 95% confidence interval 1.85-2.09) but not in older adults (adjusted reporting odds ratio 0.71; 95% confidence interval 0.59-0.84), suggesting paradoxically less acute kidney injury reporting in older SGLT2 inhibitor users[15].
Despite the apparent protective association in clinical trials and pharmacovigilance data, important clinical caution remains warranted regarding volume depletion and acute kidney injury risk. In real-world observational studies, notably increased reporting of nocturia and dehydration symptoms accompanied SGLT2 inhibitor use in both younger and older populations, and concomitant use of diuretics and antihypertensive agents was more common in patients experiencing these volume-related effects[15]. These observations suggest that while SGLT2 inhibitors may not increase acute kidney injury risk in carefully selected and monitored populations, vigilance regarding volume status remains essential, particularly in older patients receiving concurrent loop diuretics or those with underlying volume-responsive conditions[15][17].
Gastrointestinal Adverse Events
GLP-1 receptor agonists demonstrate a distinctly different safety profile regarding gastrointestinal adverse events compared with SGLT2 inhibitors, with gastrointestinal complications representing the most frequently encountered adverse events associated with GLP-1 receptor agonist therapy[18]. The gastrointestinal adverse effects of GLP-1 receptor agonists typically include nausea, vomiting, diarrhea, and constipation, occurring in forty to seventy percent of treated patients, though sometimes reported in up to eighty-five percent of recipients[18]. These gastrointestinal adverse events typically develop during the dose-escalation period and generally resolve shortly after achievement of maintenance dosing, with the majority of documented gastrointestinal adverse events being non-serious[18].
Among specific gastrointestinal adverse events, nausea emerges as the most frequent complication, with prevalence typically ranging from fifteen to fifty percent during clinical trials[18]. The onset of nausea predominantly occurs during the first four to five weeks of treatment when gastric emptying delay is most pronounced, with symptoms typically resolving within eight days or less[18]. Long-acting GLP-1 receptor agonists have been associated with less nausea and vomiting but greater diarrhea frequency, potentially reflecting more sustained effects on intestinal glucagon-like peptide-1 receptors[18]. For patients experiencing persistent nausea despite dose optimization, antiemetic and prokinetic medications including domperidone (preferentially used over metoclopramide in older patients to minimize extrapyramidal side effects) or cinitapride may provide symptom relief[18]. Importantly, gastrointestinal adverse events with GLP-1 receptor agonists have not been consistently associated with increased reporting in older populations compared with younger recipients in clinical trials[5].
SGLT2 inhibitors do not produce gastrointestinal adverse events comparable in frequency or severity to those associated with GLP-1 receptor agonists, representing a potential advantage particularly for older patients with preexisting gastrointestinal disorders or limited gastrointestinal tolerance[1]. This gastrointestinal advantage of SGLT2 inhibitors becomes clinically significant for individuals with prior gastrointestinal surgery, inflammatory bowel disease, or chronic gastrointestinal dysmotility, where GLP-1 receptor agonist-induced gastrointestinal effects might prove poorly tolerated.
Bone Fractures and Falls
Concerns regarding bone fragility and fracture risk with SGLT2 inhibitors have generated clinical discussion, particularly given the age-related increases in osteoporosis prevalence in older populations[15][17]. A borderline increased reporting of fractures with SGLT2 inhibitors was identified in real-world pharmacovigilance analyses, though this increase was not statistically significantly greater in older populations compared with younger recipients[15]. The proposed mechanism for SGLT2 inhibitor-associated fractures involves indirect effects through hypotension and falls, yet detailed pharmacovigilance analysis failed to identify increased reporting of hypotension, falls, or syncope in either age group[15]. Most randomized controlled trials have not observed increased incidence of fractures with SGLT2 inhibitors, with the notable exception of the CANVAS trial involving canagliflozin, which demonstrated increased fracture risk in this specific agent[15][17].
Meta-analytic evidence in elderly patients revealed comparable risks of fractures between SGLT2 inhibitors and placebo (risk ratio 1.0; 95% confidence interval not significantly different)[17]. Given the borderline significance of increased fracture reporting in post-marketing studies, the lack of clear biological mechanism through confirmed hypotension and falls, and the lack of consistent increases in randomized controlled trials, a robust safety signal for fractures with SGLT2 inhibitors does not appear established[15]. Nevertheless, cautious use of SGLT2 inhibitors remains reasonable in older patients with documented osteoporosis or recurrent falls, particularly in those taking concurrent medications affecting bone metabolism or balance.
GLP-1 receptor agonists have not been associated with increased fracture risk in clinical trials or post-marketing surveillance, and the potential for weight loss induced by these agents might theoretically improve skeletal loading and potentially support bone health in select populations[5]. However, the impact of GLP-1 receptor agonist-induced weight loss on bone mineral density and fracture risk remains incompletely characterized in older populations.
Amputation Risk
Amputation risk represents a particularly serious adverse event consideration with SGLT2 inhibitors, initially identified with canagliflozin in clinical trial data but subsequently examined across the broader drug class[15][17]. The CANVAS trial specifically demonstrated increased amputation risk associated with canagliflozin, predominantly affecting lower extremity amputations[15]. Subsequent post-marketing studies have demonstrated increased reporting of amputations with SGLT2 inhibitors generally, particularly pronounced with canagliflozin[15]. A meta-analysis of elderly patients found increased amputation rates only among canagliflozin users (risk ratio 1.94; 95% confidence interval 1.25-3.0), but not with empagliflozin or dapagliflozin[17].
One population-based cohort study addressing age effects on amputation risk found increased rates of amputations with SGLT2 inhibitors only in adults aged sixty-five years or older with baseline cardiovascular disease, with an event rate of 1.8 per 1,000 patients[15]. Importantly, real-world pharmacovigilance analysis failed to identify increased reporting of amputations in older adults compared with younger patients using SGLT2 inhibitors, suggesting that age alone may not substantially amplify amputation risk[15]. The amputation risk with canagliflozin specifically argues for preferential selection of other SGLT2 inhibitors (dapagliflozin or empagliflozin) in older patients, particularly those with underlying vascular disease or prior lower extremity complications.
GLP-1 receptor agonists have not been associated with amputation risk in available clinical and post-marketing data, representing another important safety distinction between these drug classes[5].
Hypoglycemia Risk
Both SGLT2 inhibitors and GLP-1 receptor agonists are associated with minimal hypoglycemia risk when used as monotherapy, representing a substantial safety advantage compared with insulin or insulin secretagogues[1][11][5][17]. Meta-analytic evidence in older adults found comparable hypoglycemia risk between SGLT2 inhibitors and placebo and between GLP-1 receptor agonists and placebo[17]. However, when either drug class is combined with insulin or sulfonylurea agents, the risk of hypoglycemia becomes amplified, necessitating dose reductions of concurrent insulin or secretagogue therapy[1][7]. Given the high prevalence of prior insulin use in older populations, careful medication reconciliation and appropriate dose adjustment of concurrent insulin therapy become essential when initiating either drug class.
Efficacy in Glycemic Control and Weight Management
While cardioprotective and renoprotective outcomes represent the primary drivers of SGLT2 inhibitor and GLP-1 receptor agonist selection in older adults with diabetes, understanding the comparative glycemic efficacy and weight management effects remains clinically relevant for comprehensive patient assessment. The evidence demonstrates important differences in the magnitude of glucose lowering between these drug classes, with implications for patients requiring more aggressive glycemic control or those at risk for weight-related complications.
GLP-1 receptor agonists achieve more substantial reductions in hemoglobin A1c compared with SGLT2 inhibitors, with meta-analytic data indicating hemoglobin A1c reductions of approximately 1.0 to 1.8 percent with GLP-1 receptor agonists depending on the specific agent and baseline control[10]. In contrast, SGLT2 inhibitors typically produce hemoglobin A1c reductions of 0.5 to 1.0 percent[1]. These glycemic differences become particularly relevant when managing older patients with poor baseline glycemic control or those approaching the threshold for insulin initiation. In older or frail patients with concurrent type 2 diabetes and heart failure, SGLT2 inhibitors did not significantly reduce hemoglobin A1c levels (mean difference −0.13; 95% confidence interval −0.41 to 0.14), demonstrating that the primary cardioprotective benefits of SGLT2 inhibitors in this population operate largely independently of glucose control[2].
Regarding weight management, GLP-1 receptor agonists demonstrate substantially greater weight reduction compared with SGLT2 inhibitors[3][9]. Weight reductions with GLP-1 receptor agonists typically range from three to six kilograms greater than with SGLT2 inhibitors, representing a clinically significant differential effect, particularly in older populations where obesity contributes substantially to cardiovascular risk, functional impairment, and metabolic dysfunction[3][9]. GLP-1 receptor agonists achieve these weight reductions primarily through delayed gastric emptying and central appetite suppression mechanisms, generating more sustained satiety than SGLT2 inhibitors, which produce modest weight loss primarily through osmotic diuresis and initial volume depletion[10].
These glycemic and weight management considerations become particularly relevant when considering clinical phenotypes in older adults. Patients presenting with sarcopenic obesity—characterized by elevated body weight concurrent with functional sarcopenia—may derive substantial benefits from GLP-1 receptor agonist-induced weight loss, though concerns regarding weight loss effects on muscle mass warrant consideration. In contrast, older adults with anorexic malnutrition phenotypes—characterized by low body weight, malnutrition, and limited glycemic control—should generally avoid GLP-1 receptor agonists due to appetite suppression effects that might exacerbate nutritional inadequacy, with long-acting insulin analogs representing more appropriate alternatives[19].
The Critical Role of Frailty Status in Drug Selection
Emerging evidence demonstrates that frailty status, rather than chronological age alone, represents the most clinically meaningful variable for guiding therapeutic decision-making between SGLT2 inhibitors and GLP-1 receptor agonists in older adults[3][20]. This distinction carries profound implications for clinical practice, as many older adults remain functionally fit and may derive substantial benefits from both drug classes, while others with moderate or severe frailty require more careful risk-benefit assessment and potentially different therapeutic approaches.
A comprehensive retrospective nationwide longitudinal study examining the effect of frailty on effectiveness and safety of GLP-1 receptor agonists versus SGLT2 inhibitors in managing type 2 diabetes identified 280,163 individuals categorized into three frailty subgroups—fit, mild frailty, and moderate or severe frailty—based on multimorbidity frailty indices[20]. Remarkably, all clinical outcomes including three-point major adverse cardiovascular events, all-cause mortality, hospitalization for heart failure, dialysis or renal transplant, severe diabetic foot complications, and retinopathy were comparable between GLP-1 receptor agonist and SGLT2 inhibitor users across each frailty subgroup, with few exceptions[20]. This finding suggests that frailty status itself does not substantially amplify the differential efficacy between these drug classes in older populations. However, specific safety concerns emerged when stratifying by frailty, with GLP-1 receptor agonist users showing higher risk of hospitalization for severe hyperglycemia in the mild frailty subgroup and higher risk of dialysis or renal transplant across all frailty categories compared with SGLT2 inhibitor recipients[20].
Additional evidence regarding adverse events stratified by frailty reveals reassuring safety profiles for both drug classes in this vulnerable population. In a large cohort study including more than 740,000 individuals with type 2 diabetes aged sixty-five years or older, both SGLT2 inhibitors and GLP-1 receptor agonists were associated with smaller numbers of cardiovascular events and death compared with dipeptidyl peptidase-4 inhibitors, with the largest benefits paradoxically being observed among frail individuals[19]. Crucially, adverse events affecting frailer individuals were not more common with SGLT2 inhibitors or GLP-1 receptor agonists than with dipeptidyl peptidase-4 inhibitors, providing important reassurance regarding the safety profile of both newer drug classes in frail populations[19].
Despite this robust evidence supporting the safety and efficacy of both SGLT2 inhibitors and GLP-1 receptor agonists in frail older adults, substantial prescribing hesitancy persists in real-world clinical practice[19]. A cross-sectional study evaluating 103,790 people with type 2 diabetes and cardiovascular disease with median age of seventy-one years categorized by frailty status demonstrated that most frail individuals were significantly less likely to receive SGLT2 inhibitors and GLP-1 receptor agonists than nonfrail counterparts despite having high risk of cardiovascular and diabetes-related events and no documented contraindications[19]. This evidence suggests that the underutilization of both drug classes in frail older adults does not appear justifiable based on the contemporary evidence base, and that implementation of frailty assessment in routine diabetes care could help identify individuals who might benefit from close monitoring for adverse reactions while deriving substantial cardioprotective benefits[19].
The optimal approach to therapeutic selection in frail older adults may involve consideration of specific phenotypic characteristics beyond frailty status alone. In older adults with sarcopenic obesity phenotypes characterized by elevated body weight and functional sarcopenia, both SGLT2 inhibitors and GLP-1 receptor agonists represent reasonable options offering cardioprotective benefits and weight loss[19]. In contrast, in older adults with anorexic malnutrition phenotypes characterized by low body weight and nutritional inadequacy, long-acting insulin analogs may be more appropriate than either SGLT2 inhibitors or GLP-1 receptor agonists, due to the anabolic effects of insulin and its lack of appetite-suppressing properties[19].
Medication Adherence and Real-World Persistence
Understanding adherence patterns with SGLT2 inhibitors and GLP-1 receptor agonists in real-world older populations provides essential context for therapeutic decision-making, as excellent efficacy in clinical trials translates into limited clinical benefit if patients discontinue medications due to tolerability concerns or adverse events. A large population-based cohort study examining adherence trajectories during the first year of SGLT2 inhibitor therapy in nearly eighty-four thousand older adults with type 2 diabetes found that the overall unadjusted mean proportion of days covered (PDC) was sixty-three percent, and only forty-five percent of patients remained adherent during the first year of therapy, defined as overall proportion of days covered of eighty percent or higher[21]. This adherence rate substantially lagged behind comparable studies utilizing commercial insurance populations, where sixty-one percent of new SGLT2 inhibitor users achieved proportion of days covered of eighty percent during their first year[21].
Notably, baseline adherence to other medications including metformin and statins was consistently associated with higher SGLT2 inhibitor adherence, whereas female sex and Black race/ethnicity were consistently associated with lower adherence[21]. These findings suggest that prior medication adherence patterns may serve as useful predictive indicators for identifying which older adults are likely to maintain SGLT2 inhibitor adherence, and that specific subpopulations warrant enhanced adherence support interventions. The temporal pattern of adherence demonstrated three distinct trajectory groups: high adherence (maintained throughout the first year), moderate adherence (maintained but declining gradually), and low adherence (rapid decline), with a substantial proportion of patients transitioning to the low adherence group during the initial months[21]. This pattern suggests that adverse events occurring early in therapy may substantially impact adherence decisions, emphasizing the importance of careful patient counseling and early recognition of potentially manageable adverse events.
Real-world evidence regarding long-term SGLT2 inhibitor use in older populations identified that mean adverse events were more prevalent in elderly patients (eighty-five years and older) than in younger patients, with adverse event prevalence of thirty-one percent in elderly populations compared with twenty-one percent in younger patients (p<0.001)[22]. Moreover, elderly patients demonstrated substantially higher discontinuation rates (fifty-two percent) compared with younger adults (thirty-three percent; p=0.005), highlighting the particular challenge of medication tolerability and persistence in the very elderly[22]. The most common adverse events necessitating consideration of discontinuation included hypoglycemia, genitourinary infections, and polyuria, findings consistent with the safety profile established in clinical trial data[22].
Comparative adherence data for GLP-1 receptor agonists suggests similar or potentially even lower adherence rates compared with SGLT2 inhibitors in older populations. Among Medicare enrollees who initiated treatment with GLP-1 receptor agonists, only thirty-seven percent achieved proportion of days covered of eighty percent during the first six months of therapy, a substantially lower adherence rate than observed with SGLT2 inhibitors in the same population[21]. This lower adherence with GLP-1 receptor agonists likely reflects the complexity of injectable administration and the substantial gastrointestinal adverse events that occur frequently during dose escalation, both factors potentially contributing to treatment discontinuation in older adults who may prioritize simplicity and tolerability.
Comparative Effectiveness in Specific Clinical Scenarios
Translating the complex evidence base regarding SGLT2 inhibitors and GLP-1 receptor agonists into practical clinical decision-making requires systematic consideration of patient-specific characteristics and clinical presentations. The contemporary evidence base supports a personalized, phenotype-based approach to drug selection rather than a categorical recommendation favoring one drug class over another for all older adults with type 2 diabetes.
In older patients with established heart failure and reduced ejection fraction, the evidence strongly favors SGLT2 inhibitors as preferred initial agents for addressing both diabetes and heart failure management[1][2][3][4]. SGLT2 inhibitors consistently demonstrate superior efficacy in reducing heart failure hospitalizations and all-cause mortality in this population compared with GLP-1 receptor agonists[2][4]. The combination of cardiorenal protection and the minimal hypoglycemia risk makes SGLT2 inhibitors an ideal choice for older patients with concurrent diabetes and systolic heart failure.
In older patients with advanced chronic kidney disease (stages 3b through 4, with estimated glomerular filtration rate 20-45 mL/min/1.73m²) or those approaching end-stage renal disease, SGLT2 inhibitors demonstrate superior renoprotection compared with GLP-1 receptor agonists[3][14]. The substantial reduction in estimated glomerular filtration rate decline and the prevention of end-stage kidney disease progression specifically support SGLT2 inhibitor selection in this population, though careful monitoring of volume status and electrolytes becomes essential.
In older patients with poor glycemic control (hemoglobin A1c greater than 8 percent) or those at high stroke risk, GLP-1 receptor agonists may be preferentially selected given their superior glycemic efficacy and stroke protection[3][5][8][9]. The more substantial hemoglobin A1c reduction of GLP-1 receptor agonists becomes particularly relevant when approaching the threshold for insulin initiation or when glycemic control substantially impacts glucose toxicity and diabetic complication risk.
In older patients with obesity and type 2 diabetes, GLP-1 receptor agonists offer substantial advantages through weight reduction effects substantially exceeding those of SGLT2 inhibitors[3][9]. The weight loss benefits extend beyond metabolic improvements to potentially enhance mobility, reduce joint stress, and improve functional independence in older adults where such considerations substantially impact quality of life.
In older patients with recurrent genital candidiasis or those with prior genitourinary infection history, GLP-1 receptor agonists should be preferentially selected given the six-fold increased genital infection risk with SGLT2 inhibitors[16][17]. This consideration particularly impacts older women who may have reduced tolerance for recurrent genital infections.
In older patients with prior gastrointestinal disorders, surgery, or chronic dysmotility, SGLT2 inhibitors may be preferentially selected given the substantial gastrointestinal adverse event burden associated with GLP-1 receptor agonists[18]. The forty to seventy percent incidence of gastrointestinal adverse events in GLP-1 receptor agonist recipients becomes prohibitive for patients with limited gastrointestinal reserve.
In older patients with intermediate cardiovascular risk requiring diabetes management without established cardiovascular disease or heart failure, either drug class may be appropriately selected based on consideration of glycemic targets, renal function, weight status, and other phenotypic characteristics[3][9][20]. The comparable cardiovascular event reduction between SGLT2 inhibitors and GLP-1 receptor agonists in primary prevention settings permits personalization based on tolerability and organ-specific protection needs.
Dual Therapy: Emerging Evidence for Combination Therapy
Contemporary evidence increasingly supports the use of combined SGLT2 inhibitors and GLP-1 receptor agonist therapy in select older patients, particularly those with multiple cardiometabolic risk factors or those requiring more intensive glycemic control. The therapeutic rationale for combination therapy reflects the complementary mechanisms of these drug classes, with SGLT2 inhibitors providing specific heart failure and renal protection while GLP-1 receptor agonists provide superior glycemic control, weight reduction, and stroke protection[3][23].
The metabolic effects of combined SGLT2 inhibitors and GLP-1 receptor agonist therapy address seven of the eight mechanisms comprising the "ominous octet" of metabolic dysfunction in type 2 diabetes, addressing all components except adipocyte insulin resistance[23]. Initial clinical trial evidence including DURATION-8 (dapagliflozin and exenatide), AWARD-10 (dulaglutide and SGLT-2 inhibitor), and SUSTAIN-9 (semaglutide and SGLT-2 inhibitor) demonstrated additive benefits of combination therapy on glycemic control, weight loss, systolic blood pressure reduction, and nonalcoholic fatty liver disease improvement[23]. Meta-analytic evidence indicates that GLP-1 receptor agonist treatment reduces cardiovascular adverse event risk independently of SGLT2 inhibitor use, without increased serious adverse events[23].
The American Diabetes Association recommendations for adults with type 2 diabetes and established or high-risk atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease include both SGLT2 inhibitors and GLP-1 receptor agonists with demonstrated cardiovascular benefits as components of glycemic management, independent of hemoglobin A1c levels or metformin use[3][23]. Emerging evidence suggests that combined use of both drug classes may provide additive benefits beyond monotherapy for cardiovascular and renal protection[23]. In older patients with concurrent heart failure and chronic kidney disease requiring intensive cardioprotection, combination therapy may be particularly justified despite the increased complexity and cost considerations[3][23].
However, important practical considerations limit the real-world adoption of dual therapy in older populations. The additive adverse events of both drug classes become more concerning in older adults with baseline tolerability concerns, the substantial additional cost of dual therapy may be prohibitive in resource-constrained settings, and the evidence supporting dual therapy remains predominantly derived from younger clinical trial populations rather than older individuals[23]. Additionally, head-to-head clinical trials specifically comparing dual therapy efficacy and safety in older populations remain lacking, limiting evidence-based recommendations for this approach in geriatric practice[23].
Evidence Gaps and Uncertainties in Older Populations
Despite substantial evidence supporting the use of both SGLT2 inhibitors and GLP-1 receptor agonists in older adults, critical evidence gaps persist that limit the precision of therapeutic recommendations. Most critically, older adults aged seventy-five years and above remain substantially underrepresented in randomized controlled trials evaluating both drug classes, with the mean age of trial participants typically ranging from sixty to seventy years[2][4][17]. This age gap creates substantial uncertainty regarding the efficacy and safety profiles in very elderly populations, where physiological reserve is reduced and the tolerance for adverse events may be limited[2].
The representation of frail older adults in clinical trials remains particularly inadequate, with most trials excluding patients with advanced frailty, multiple comorbidities, or limited life expectancy[2][17]. This creates a critical evidence vacuum regarding the specific use of SGLT2 inhibitors and GLP-1 receptor agonists in the most vulnerable older populations who would benefit most from understanding these drugs' risk-benefit profiles. Future clinical research must prioritize the inclusion of representative older populations, with explicit stratification by frailty status and detailed reporting of adverse events relevant to geriatric populations[2][17][19].
The impact of both drug classes on skeletal muscle mass remains incompletely characterized in older populations[19]. While GLP-1 receptor agonists promote weight loss, the relative contributions of fat mass and lean mass loss remain uncertain, with particular relevance for sarcopenic older adults where unintended muscle loss might exacerbate functional impairment[19]. Similarly, the long-term effects of SGLT2 inhibitors on muscle metabolism and skeletal muscle mass in older populations remain understudied[19].
The mechanisms underlying the paradoxically lower acute kidney injury rates observed with SGLT2 inhibitors in older populations compared with younger recipients require further investigation, as this apparent safety advantage contradicts biological expectations regarding age-related renal reserve and volume-responsiveness[15][17]. Understanding these counterintuitive findings would substantially enhance clinical confidence in SGLT2 inhibitor use in older patients with chronic kidney disease.
The comparative effectiveness of SGLT2 inhibitors versus GLP-1 receptor agonists for specific complications of diabetes including retinopathy, neuropathy, and severe hypoglycemia episodes remains incompletely characterized, particularly in older populations where these complications substantially impact quality of life and functional independence[20].
Pathophysiological Interactions and Comorbidity Considerations
Understanding the physiological interactions between SGLT2 inhibitors and GLP-1 receptor agonists and common comorbidities in older adults remains essential for optimizing therapeutic selection and monitoring. Many older adults with type 2 diabetes present with concurrent cardiovascular disease, chronic kidney disease, heart failure, atrial fibrillation, and other conditions that influence both drug efficacy and safety considerations.
The osmotic diuretic effect of SGLT2 inhibitors creates complex hemodynamic interactions in older patients receiving concurrent loop diuretics or other antihypertensive agents. Additive blood pressure reduction and enhanced diuresis may substantially increase hypotension and electrolyte abnormality risk, particularly in volume-depleted states or those with underlying severe renal impairment[1][15][7]. Conversely, the modest blood pressure reduction with SGLT2 inhibitors, averaging three to four millimeters mercury systolic reduction, may benefit older patients with resistant hypertension requiring intensified blood pressure control[7].
GLP-1 receptor agonists' delayed gastric emptying effects interact substantially with other agents affecting gastrointestinal motility, including anticholinergic medications frequently used in older populations for diverse indications. Enhanced gastrointestinal adverse events may occur when GLP-1 receptor agonists are combined with other agents delaying gastric emptying, while reduced efficacy might occur with concurrent antiemetic medications[18].
The potential for both drug classes to interact with insulin and insulin secretagogues necessitates substantial dose reductions of these concurrent agents to prevent hypoglycemia, creating important medication management implications for older patients frequently receiving insulin therapy[1][5][7]. The insulin-sparing effects of both drug classes represent an important safety advantage for older patients at high hypoglycemia risk.
Clinical Recommendations and Practical Implementation
Based on comprehensive analysis of contemporary clinical evidence, several evidence-based recommendations emerge for therapeutic selection between SGLT2 inhibitors and GLP-1 receptor agonists in older adults with type 2 diabetes. These recommendations emphasize individualized, phenotype-based approaches rather than categorical recommendations favoring one drug class uniformly.
First, frailty status should be systematically assessed in all older adults with type 2 diabetes, as frailty represents the most clinically meaningful variable for predicting tolerance and benefit from SGLT2 inhibitors and GLP-1 receptor agonists[3][19]. Fit older adults aged sixty-five to seventy-five years without substantial functional impairment should generally receive cardioprotective medications from either drug class based on phenotypic considerations. Mildly frail and moderately to severely frail older adults remain candidates for both drug classes, with adverse event monitoring being particularly important[19].
Second, organ-specific protection needs should substantially influence therapeutic selection. Patients with heart failure with reduced ejection fraction should preferentially receive SGLT2 inhibitors as initial agents given the superior heart failure hospitalization reduction[1][2][4]. Patients with advanced chronic kidney disease should preferentially receive SGLT2 inhibitors given superior renal protection[3][14]. Patients with prior stroke or those at high stroke risk should preferentially receive GLP-1 receptor agonists given superior stroke protection[3][5][8].
Third, metabolic phenotyping should guide selection in patients without specific organ-system indications for one drug class. Obese older adults with poor glycemic control should preferentially receive GLP-1 receptor agonists given superior weight loss and glycemic effects[3][9]. Malnourished older adults with low body weight should preferentially receive SGLT2 inhibitors or long-acting insulin rather than GLP-1 receptor agonists, which may exacerbate nutritional inadequacy[19].
Fourth, safety considerations should be systematically evaluated. Patients with recurrent genital candidiasis should preferentially receive GLP-1 receptor agonists given the high genital infection risk with SGLT2 inhibitors[16][17]. Patients with prior gastrointestinal disorders or limited gastrointestinal tolerance should preferentially receive SGLT2 inhibitors given the substantial gastrointestinal adverse event burden with GLP-1 receptor agonists[18]. Patients at particular risk for euglycemic diabetic ketoacidosis (those using SGLT2 inhibitors for diabetes management, those prone to acute illness episodes, and those adopting low-carbohydrate diets) should receive intensive patient education and close monitoring[6].
Fifth, combination therapy with both SGLT2 inhibitors and GLP-1 receptor agonists should be considered in older patients with multiple cardiometabolic risk factors including heart failure, advanced chronic kidney disease, and poor glycemic control, though careful monitoring and consideration of tolerability and cost become essential[3][23].
Sixth, baseline medication adherence patterns should be assessed, as prior adherence to other medications predicts adherence to SGLT2 inhibitors and GLP-1 receptor agonists[21]. Patients with documented poor adherence to other medications may benefit from simplified regimens with once-daily dosing and careful selection of agents with favorable tolerability profiles.
Seventh, regular monitoring intervals should be established for all older adults receiving SGLT2 inhibitors or GLP-1 receptor agonists, with particular attention to volume status, renal function, electrolytes, blood glucose patterns, and emerging adverse events[1][7]. Monitoring intervals should be more frequent in the initial weeks and months of therapy when adverse events are most likely to emerge and medication tolerability is being assessed.
Conclusions and Future Directions
The comparison between SGLT2 inhibitors and GLP-1 receptor agonists in older adults with type 2 diabetes reveals a complex landscape of differential benefits and distinct safety considerations that require systematic, individualized assessment rather than categorical recommendations favoring one drug class universally. Both drug classes have emerged as fundamental components of modern diabetes care, with evidence supporting their use across diverse older adult populations ranging from fit, active individuals to those with profound frailty and multiple comorbidities. The SGLT2 inhibitor class demonstrates particularly robust evidence for heart failure prevention and renal disease slowing, making these agents optimal choices for older patients with these specific complications. GLP-1 receptor agonists provide superior glycemic control, weight loss, and stroke prevention, making them preferentially selected for older patients with these specific needs.
The persistent hesitancy to prescribe both drug classes to older frail adults despite robust evidence supporting their safety and efficacy represents an evidence-practice gap that warrants urgent attention in clinical education and healthcare system implementation[19]. The absence of disproportionate adverse event burden in frail older populations receiving these medications provides reassurance that age and frailty alone should not represent contraindications to SGLT2 inhibitor or GLP-1 receptor agonist therapy.
Future clinical research must prioritize the inclusion of representative older populations, particularly those aged seventy-five years and beyond and those meeting criteria for moderate to severe frailty, to establish evidence-based recommendations tailored specifically to geriatric populations[2][17][19]. Studies comparing dual therapy with SGLT2 inhibitors and GLP-1 receptor agonists specifically in older populations remain critically needed to establish whether the theoretical additive benefits observed in younger cohorts translate into enhanced cardiovascular and renal protection in older individuals. Investigation of the impact of both drug classes on skeletal muscle mass, physical function, and quality of life outcomes would substantially enhance the clinical relevance of efficacy assessments in older populations.
The implementation of systematic frailty assessment in routine diabetes care would enhance therapeutic precision and facilitate identification of older individuals who might benefit from close monitoring for adverse reactions while deriving substantial cardioprotective and renoprotective benefits[19][20]. Investment in medications that demonstrate compatibility with older adults' life priorities and functional goals, rather than exclusive focus on glycemic control, would likely enhance medication adherence and clinical outcomes in this complex population.
In conclusion, both SGLT2 inhibitors and GLP-1 receptor agonists represent valid therapeutic options for older adults with type 2 diabetes, with therapeutic selection appropriately guided by organ-specific protection needs, metabolic phenotyping, safety considerations, and individual patient preferences within the context of personalized, comprehensive geriatric assessment. The evidence supporting the use of both drug classes in frail older populations should substantially reduce clinical prescribing hesitance and enable more older adults to benefit from the substantial cardioprotective and renoprotective advances that these medications provide.
Fuentes
- https://pmc.ncbi.nlm.nih.gov/articles/PMC9536439/
- https://academic.oup.com/ageing/article/53/1/afad254/7591145
- https://pmc.ncbi.nlm.nih.gov/articles/PMC11788569/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC11274864/
- https://pubmed.ncbi.nlm.nih.gov/40812084/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC11277626/
- https://www.cardioteca.com/blog-diabetes/464-inhibidores-sglt2/4556-el-papel-de-los-inhibidores-del-cotransportador-de-sodio-glucosa-2-en-adultos-mayores-fragiles-con-o-sin-diabetes-mellitus-tipo-2.html
- https://pmc.ncbi.nlm.nih.gov/articles/PMC11326472/
- https://academic.oup.com/ckj/article/18/2/sfae380/7915084
- https://beyondtype1.org/es/medicamentos-sglt2-glp1-corazon/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC12417164/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC10932840/
- https://pubmed.ncbi.nlm.nih.gov/34780865/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC11141184/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC9875397/
- https://pubmed.ncbi.nlm.nih.gov/31264755/
- https://pubmed.ncbi.nlm.nih.gov/37402697/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC9821052/
- https://diabetesjournals.org/care/article/47/4/e32/154361/Comment-on-Kutz-et-al-Comparative-Cardiovascular
- https://pubmed.ncbi.nlm.nih.gov/39284334/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC8918201/
- https://pubmed.ncbi.nlm.nih.gov/38771472/
- https://revistasad.com/index.php/diabetes/article/view/992
- https://www.cardioteca.com/blog-diabetes/5951-comparacion-de-isglt2-y-arglp-1-en-diabetes-tipo-2-resultados-renales-y-cardiovasculares.html
- http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034-75232022000400002
Respuesta generada por inteligencia artificial a partir de las fuentes citadas. Verifica las fuentes antes de aplicarla.